Remdesivir for the Treatment of Covid-19 — Final Report
2020/05/22 by John H. Beigel, Kay M Tomashek, Lori E. Dodd +37 · 55 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #Pharmacological Receptor Mechanisms and Effects #SARS-CoV-2 and COVID-19 Research
paper · doi:10.1056/nejmoa2007764
openalex publication_date 2020/05/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30
Abstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
Citations
Cited by
- Implementation of an Online Drug–Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19
- Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity
- Mechanisms of SARS-CoV-2 entry into cells
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
- A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?
- Accelerating antiviral drug discovery: lessons from COVID-19
- Bayes factors for two-group comparisons in Cox regression with an application for reverse-engineering raw data from summary statistics
- SARS-CoV-2 viral remnants and implications for inflammation and post-acute infection sequelae
- Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
- A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (Mpro) of SARS-CoV-2 and MERS-CoV
- In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
- Characteristics of SARS-CoV-2 and COVID-19
- COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis
- Systemic and organ-specific immune-related manifestations of COVID-19
- Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication
- Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials
- Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors
- Bayesian transition models for ordinal longitudinal outcomes
- Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical Review
- COVID-19 in patients with hematologic malignancy
- Computational drug repurposing: approaches, evaluation of in silico resources and case studies
- Structure-guided design of potent and selective covalent inhibitors of SARS-CoV-1 and SARS-CoV-2 papain-like proteases with antiviral activity
- Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data
- An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
- Security of Healthcare Data Using Blockchains: A Survey
- Mechanism and spectrum of inhibition of viral polymerases by 2′-deoxy-2′-β-fluoro-4′-azidocytidine or azvudine
- A post-assembly conformational change makes the SARS-CoV-2 polymerase elongation-competent
- Ebola virus persistence: implications for human-to-human transmission and new outbreaks
- Dexamethasone in Hospitalized Patients with Covid-19
- Dexamethasone in Hospitalized Patients with Covid-19.
- Approximate Bayesian Computation for an Explicit-Duration Hidden Markov Model of COVID-19 Hospital Trajectories
- Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
- Toward Personalized Medicine: The Effect of Treatment of Chronic Enterovirus Diarrhea in an Immunocompromised Patient and the Correlation With In Vitro Models
- Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- Coronaviruses: Pandemic SARS-CoV-2
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
- Reparations for Black American descendants of persons enslaved in the U.S. and their potential impact on SARS-CoV-2 transmission
- A living WHO guideline on drugs for covid-19 (2020-2023)
- The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- RETRACTED: Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate
- COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
- A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
- Coronavirus vaccine development: from SARS and MERS to COVID-19
- Four months into the COVID-19 pandemic, Sweden’s prized herd immunity is nowhere in sight
- Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients
- A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
- BridgeDPI: A Novel Graph Neural Network for Predicting Drug-Protein Interactions
- Causal discovery using compression-complexity measures
- Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost
- Impacto de la Covid-19 en las personas con discapacidades intelectuales y del desarrollo, sus familiares y los profesionales y organizaciones de apoyo
- Youden’s J and the Bi Error Method
- Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
Related